Product
ME-401
4 clinical trials
9 indications
Indication
Chronic Lymphocytic LeukemiaIndication
small lymphocytic lymphomaIndication
Follicular LymphomaIndication
Marginal Zone B Cell LymphomaIndication
Diffuse Large B-cell LymphomaIndication
High Grade Non-Hodgkin's LymphomaIndication
Mantle Cell LymphomaIndication
Indolent B-cell Non-Hodgkin's LymphomaIndication
Diffuse Large B-Cell LymphomaClinical trial
A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHLStatus: Terminated, Estimated PCD: 2023-03-29
Clinical trial
A Japanese Phase 2 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Japanese Phase 1 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma and Roll Over Study for Subjects Who Have Participated in ME-401-004 StudyStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
An Open-Label, Phase I/II Study of ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01